Navigation Links
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Date:9/3/2013

NEW YORK, September 3, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting CareFusion Corporation (NYSE: CFN), St. Jude Medical, Inc. (NYSE: STJ), Community Health Systems Inc. (NYSE: CYH), Neurocrine Biosciences, Inc. (NASDAQ: NBIX), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

CareFusion Corporation Research Report  

On August 27, 2013, CareFusion Corporation (CareFusion) announced that the Company has simplified the ordering process for its line of surgical products through an interactive e-catalog portal. According to CareFusion, the new time-saving ordering system includes more than 12,000 different products that are easily searched and sorted based on the product name or the type of specialty in which they are used. CareFusion informed that the new system includes pre-built and recommended trays for more than 25 common procedures from nine different specialty areas including Cardiovascular, Ear Nose and Throat, General and Micro Surgery, Laparoscopic Surgery, Neurology and Spine, Obstetrics and Gynecology, Ophthalmic, Oral Surgery, and Orthopedic. The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4933_CFN]

St. Jude Medical, Inc. Research Report

'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
2. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
3. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
4. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
8. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
9. Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... PHIA) today announced its presence at  ESC Congress 2015 , where ... Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... SPEX ) announced today that it has signed letters ... pharmaceutical ingredients,to supply a portion of the D-tagatose used ... sugar as a treatment for Type 2 diabetes. Inalco ... D- tagatose for the Spherix New Drug Application (NDA) ...
... today announced that it submitted a supplemental New ... Administration (FDA) for approval of a new,indication for ... of patients with Chronic Obstructive,Pulmonary Disease (COPD). SYMBICORT ... asthma in patients 12 years and older., ...
Cached Medicine Technology:Spherix D-tagatose to be Supplied by Inalco SpA 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 3AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 4AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 5
(Date:8/29/2015)... ... 2015 , ... Vascular Health Sciences announced today that an ... HP, and that all claims and counterclaims have been irrevocably dismissed. , In ... the United States District Court for the Southern District of Texas for breach ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... ... 28, 2015 , ... As reported by Medical Daily on August 22 ... results that last for two years, the longest of any cellulite reduction system currently ... for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers how this software allows businesses to track product movement from beginning to end. ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for its adolescent residential, counseling, day treatment and intensive family based services. , ... standards for quality and its pursuit of excellence. As a nonprofit charity for ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... Haryana government claimed Monday that there was a minor improvement in ... the lowest figure in the country., ,Latest reports suggested that ... now at 822 females per thousand males, director general of health ... had recorded an abysmally low ratio of 819, which placed it ...
... had published a research report on recommendations to ... health-worker performance is a widespread problem for // ... of The Lancet researchers had reviewed the existing ... performance can be achieved., ,Millions of children ...
... Science is usually viewed with awe, not to mention a little ... people cannot understand, let alone hope to enter. Such an // ... the use of science., ,If the public is to have ... it should fist have a clear sense of what science can ...
... second largest number of HIV/AIDS afflicted people in the world ... of India are very real according to a World Economic ... businesses expect an effect on the business due to AIDS ... surveyed recently and 46 per cent report some ...
... The Office of Fair Trading is responsible for checking ... //manufacturers sell to the NHS. They have to monitor ... the prices should be reasonable. ,The Pharmaceutical ... monitors and legislates the agreement of the pricing and ...
... a disaster-planning guide to help the people who live ... hurricanes, tidal waves and cyclones. ,No matter where ... some sort of natural disaster such as a blizzard, ... are also possible. Both natural disasters and terrorist attacks ...
Cached Medicine News:Health News:Scientists Awarded Appropriately For Contribution Towards Medical Research 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2
... Test, v1.5, an FDA-approved HIV-1 RNA assay, is ... used in the regulatory approval for HIV-1 therapies, ... 10 clinical laboratories worldwide. , The ... vitro nucleic acid amplification test for the quantification ...
... ADVANCE Rapid HIV-1/2 Antibody ... qualitative immunoassay to detect ... Virus Type 1 (HIV-1) ... in oral fluid, fingerstick ...
... CHS System takes the time proven technology ... ,The VHS® Supracondylar Cable Plate is designed ... femur fractures including periprosthetic fractures. The combination ... angle of the barrel and the plate ...
Corneal Marking Pen - Sterile. 10 pieces/box...
Medicine Products: